Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108741 | PMC |
| http://dx.doi.org/10.1111/jch.12020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Induced Systemic Lupus Erythematosus: A Rare Presentation of Hydralazine-Induced Lupus.
Cureus
October 2024
Internal Medicine, Arrowhead Regional Medical Center, Colton, USA.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by the production of autoantibodies directed against nuclear and cytoplasmic antigens. SLE can be induced by various medications, such as hydralazine, procainamide, isoniazid, methyldopa, chlorpromazine, quinidine, and minocycline. Hydralazine-induced lupus syndrome was first reported in 1953, and only occurs in 5-10% of patients taking hydralazine.
View Article and Find Full Text PDFManifestations of Hydralazine-Induced Vasculitis: A Case Series.
Cureus
October 2024
Internal Medicine, Northeast Georgia Medical Center Gainesville, Gainesville, USA.
Article Synopsis
- Hydralazine has been used for many years to treat high blood pressure, but it can cause serious side effects, including autoimmune diseases like ANCA-vasculitis and a lupus-like syndrome.
- The text discusses four cases of vasculitis linked to hydralazine, showing varying symptoms like lung hemorrhage, coughing up blood, and skin rashes.
- Diagnosing these conditions can be challenging, often requiring kidney biopsy, and the treatment involves stopping hydralazine and using immunosuppressants; caution is advised in using hydralazine over other blood pressure medications.
In vivo ameliorative effects of vitamin E against hydralazine-induced lupus.
Lupus Sci Med
November 2023
Biochemistry, Microbiology and Biotechnology, Kenyatta University School of Pure and Applied Sciences, Nairobi, Kenya.
Objective: In this study, we investigated the in vivo ameliorative effects of vitamin E in a hydralazine-induced lupus model, which closely resembles SLE in humans. We aim to shed light on its potential as a therapeutic agent for managing SLE.
Methods: Forty BALB/c mice were used in this study.
A Rare Presentation of Hydralazine-Induced Lupus in the Setting of Pericarditis With Concomitant Angioedema.
Cureus
May 2023
Internal Medicine, Summa Health, Akron, USA.
Drug-induced lupus (DIL) usually presents after starting a medication known to induce DIL. However unusual presentations are rare, as such, our patient presented with initial signs and symptoms of pericarditis. Once treated as such, he progressively declined to symptoms of angioedema and worsening cardiopulmonary status.
View Article and Find Full Text PDFThe Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis.
Case Rep Pulmonol
April 2023
Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Hydralazine is a vasodilator used for the management of hypertension, heart failure, and hypertensive emergencies in pregnancy. It has been implicated in the causation of drug-induced lupus erythematosus (DLE) and rarely with ANCA-associated vasculitis (AAV), which may present as a pulmonary-renal syndrome and be rapidly fatal. Herein, we describe a case of hydralazine-associated AAV presenting as acute kidney injury with the use of early bronchoalveolar lavage (BAL) with serial aliquots to aid with diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!